Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

December 28, 2017 by Alan Khadavi

Severe Hives Treatment (Xolair and Cyclosporine)

Severe hives or chronic spontaneous urticaria is classified as hives with or without swelling that occurs for 6 weeks or more with an unknown cause.  The prevalence of chronic hives (also known as chronic idiopathic urticaria) is approximately 0.5% to 5% of the population.  Chronic hives may be active for 1-5 years at a time, but in some cases in can relapse, lasting several years.  Although guidelines outline several options for chronic hives, some patients with severe hives may resort to last-line therapies.  The 2 mainstay treatments for these cases of severe hives are, Xolair (omalizumab) and cyclosporine.

First line treatment for chronic hives is the use of a second generation antihistamine (i.e. cetirizine, fexofenadine) up to 4 times a day.  In addition, an H2-receptor antagonist (Zantac) and a leukotriene receptor antagonist (Singulair) is often used.  If this fails, a potent (but sedating) antihistamine such as hydroxyzine or doxepin can be tried.  If all of this fails, the next step for severe hives are omalizumab (which is FDA approved) or cyclosporine.

Stepwise approach to Chronic Urticaria (Chronic Hives)

Xolair is a monoclonal antibody against IgE and it is the first biologic agent approved for chronic spontaneous urticaria.  It is administered at a dose of 150mg or 300mg every 4 weeks.  The duration of treatment has not been determined, so patients should be monitored for resolution of urticaria.  IgE levels during treatment is not recommended.  Patients should be monitored for adverse drug reactions, including anaphylaxis and injection site reactions on administration.

Cyclosporine is an immunosuppressant that is used off label for severe hives that has been studied at a dose of 1 to 5 mg/kg daily.  Cyclosporine is available in modified and unmodified versions.  Unmodified has less absorption than the modified version, making them not interchangeable.  Before starting treatment, blood pressure needs to be checked on 2 separate occasions and baseline labs needed are; blood urea nitrogen, serum creatine, CBC, magnesium, lipids, potassium and uric acid.  Throughout treatment, labs should be drawn monthly.  Adverse effects that need to be monitored are gum hyperplasia, hypertension, renal dysfunction, tremor and hirsutism.  Patients are also at an increased risk of infections and should be monitored.  Other treatments that have less supporting evidence are hydroxychloroquine, dapsone, methotrexate, sulfasalazine or IVIG.

In conclusion, both agents are effective for severe hives.  Xolair is most effective at 300 mg every 4 weeks and cyclosporine 1 to 5 mg/kg daily.  Both drugs should be used as last line option for severe hives.  Xolair is approved by FDA for chronic hives, whereas cyclosporine is not.  Both are feasible options for severe hives.    The cost though is vastly different.  Xolair at 300mg a month, will be approximately $2000 monthly, including medication and administration fees.   Cyclosporine would be around $100/month, including medication costs and lab fees.   As always, speak to your allergy doctor to see which medication is right for you if your hives are persisting despite step 1 therapy.

Alternative Agents for Refractory Chronic Urticaria Patients

FDA approves Xolair for Chronic Urticaria

Update September 11, 2023

A recent study titled “Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation looked at changing the dosing regimen for responders and non-responders.

For Responders: After the first 6 treatments, interval lengthening should progress after every 2 treatments. If a patient responds and is getting it every 10 weeks with complete response, Xolair can be tried to be discontinued.

  • 300mg q5 weeks
  • 300mg q6 weeks
  • 300mg q7 weeks
  • 300mg q8 weeks

For Non Responders: After 3 months of treatment, Xolair should be updosed or the interval should be shortened. Different regimens proposed were:

  • 450mg q4 weeks
  • 450mg q3 weeks
  • 600mg q4 weeks
  • 600mg q3 weeks
  • 600mg q2 weeks

Xolair interval and dosing adjustments is both effective and safe and should be implemented for non-responders and responders with the regimens above.

Filed Under: Blog, Urticaria

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page